Integra LifeSciences Posts Q3 Profit; Reaffirms FY26 Outlook
Integra LifeSciences (IART) reported Q3 2026 revenue of $411.2M, up 2.3% YoY, and returned to profitability with GAAP net income of $14.9M. Adjusted EPS rose to $0.59. The company reaffirmed its FY26 outlook, expecting revenue of $1.634B-$1.654B and adjusted EPS of $2.30-$2.40.
How this was made
The 30-second read
Why it matters
Earnings and guidance provide fresh data for valuation models; pre‑market price decline suggests immediate market reaction.
Market read
The earnings release is the primary catalyst for short‑term price movement in IART.
What to watch
Potential upside from flood‑damage insurance recovery and upcoming product launches not reflected in guidance.
Background
Integra LifeSciences reported Q3 results, returning to profitability and completed a $2.1 bn debt refinancing.
Ticker impact
Q3 2026 earnings released with profit and reaffirmed FY26 outlook; premarket price down 4.35% on the news.
likely downward pressure as market prices in modest guidance and higher debt load
Profit after loss and reaffirmed outlook were expected; guidance range is flat, prompting sell pressure.
Market effects
Medical device sector may see slight pullback as peers watch Integra's debt refinancing and modest growth.
U.S. biotech/medical stocks could face short‑term pressure.
Limited to investors focused on U.S. healthcare equities.
Counterpoint
If the market overreacts to modest guidance, a bounce could occur on the debt refinancing flexibility.
Key entities
- CompanyIntegra LifeSciences Holdings Corp.
Medical device manufacturer (ticker IART).
